325 related articles for article (PubMed ID: 11599657)
21. Platinum pharmacokinetics in sulphur-crested cockatoos (Cacatua galerita) following single-dose cisplatin infusion.
Filippich LJ; Bucher AM; Charles BG
Aust Vet J; 2000 Jun; 78(6):406-11. PubMed ID: 10920780
[TBL] [Abstract][Full Text] [Related]
22. Association of cisplatin nephrotoxicity with patient characteristics and cisplatin administration methods.
Stewart DJ; Dulberg CS; Mikhael NZ; Redmond MD; Montpetit VA; Goel R
Cancer Chemother Pharmacol; 1997; 40(4):293-308. PubMed ID: 9225947
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics of free and total platinum species after rapid and prolonged infusions of aqua (1,1-bis(aminomethyl)cyclohexane) sulfatoplatinum (II) (spiroplatin) during a phase I trial.
van der Vijgh WJ; Elferink F; Vermorken JB; ten Bokkel Huinink WW; Klein I; Gall HE; Simonetti G; McVie JG; Pinedo HM
Eur J Cancer Clin Oncol; 1988 Apr; 24(4):621-7. PubMed ID: 3383966
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics and toxicodynamics of cisplatin and its metabolites in rats: relationship between renal handling and nephrotoxicity of cisplatin.
Hanada K; Ninomiya K; Ogata H
J Pharm Pharmacol; 2000 Nov; 52(11):1345-53. PubMed ID: 11186242
[TBL] [Abstract][Full Text] [Related]
25. Comparative study of the acute nephrotoxicity from standard dose cisplatin +/- ifosfamide and high-dose chemotherapy with carboplatin and ifosfamide.
Hartmann JT; Fels LM; Franzke A; Knop S; Renn M; Maess B; Panagiotou P; Lampe H; Kanz L; Stolte H; Bokemeyer C
Anticancer Res; 2000; 20(5C):3767-73. PubMed ID: 11268452
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics of cisplatin in combined cisplatin and 5-fluorouracil therapy: a comparative study of three different schedules of cisplatin administration.
Ikeda K; Terashima M; Kawamura H; Takiyama I; Koeda K; Takagane A; Sato N; Ishida K; Iwaya T; Maesawa C; Yoshinari H; Saito K
Jpn J Clin Oncol; 1998 Mar; 28(3):168-75. PubMed ID: 9614438
[TBL] [Abstract][Full Text] [Related]
27. Platinum-DNA adduct formation in leucocytes of children in relation to pharmacokinetics after cisplatin and carboplatin therapy.
Peng B; Tilby MJ; English MW; Price L; Pearson AD; Boddy AV; Newell DR
Br J Cancer; 1997; 76(11):1466-73. PubMed ID: 9400943
[TBL] [Abstract][Full Text] [Related]
28. A phase I study in paediatric patients to evaluate the safety and pharmacokinetics of SPI-77, a liposome encapsulated formulation of cisplatin.
Veal GJ; Griffin MJ; Price E; Parry A; Dick GS; Little MA; Yule SM; Morland B; Estlin EJ; Hale JP; Pearson AD; Welbank H; Boddy AV
Br J Cancer; 2001 Apr; 84(8):1029-35. PubMed ID: 11308249
[TBL] [Abstract][Full Text] [Related]
29. Effect of buthionine sulphoximine, glutathione and methimazole on the renal disposition of cisplatin and on cisplatin-induced nephrotoxicity in rats: pharmacokinetic-toxicodynamic analysis.
Hanada K; Mukasa Y; Nomizo Y; Ogata H
J Pharm Pharmacol; 2000 Dec; 52(12):1483-90. PubMed ID: 11197076
[TBL] [Abstract][Full Text] [Related]
30. cis-Diamminedichloroplatinum(II) given in low-dose continuous infusion with concurrent radiotherapy to patients affected by inoperable lung carcinoma: a pharmacokinetic approach.
Morazzoni F; Canevali C; Zucchetti M; Caroli S; Alimonti A; Petrucci F; Giudice G; Masoni E; Bedini AV
J Cancer Res Clin Oncol; 1998 Jan; 124(1):37-43. PubMed ID: 9498833
[TBL] [Abstract][Full Text] [Related]
31. Persistent nephrotoxicity during 10-year follow-up after cisplatin or carboplatin treatment in childhood: relevance of age and dose as risk factors.
Skinner R; Parry A; Price L; Cole M; Craft AW; Pearson AD
Eur J Cancer; 2009 Dec; 45(18):3213-9. PubMed ID: 19850470
[TBL] [Abstract][Full Text] [Related]
32. Population Pharmacokinetic-Toxicodynamic Modeling and Simulation of Cisplatin-Induced Acute Renal Injury in Rats: Effect of Dosing Rate on Nephrotoxicity.
Fukushima K; Okada A; Sasaki K; Kishimoto S; Fukushima S; Hamori M; Nishimura A; Shibata N; Shirai T; Terauchi R; Kubo T; Sugioka N
J Pharm Sci; 2016 Jan; 105(1):324-32. PubMed ID: 26852862
[TBL] [Abstract][Full Text] [Related]
33. Population pharmacokinetic analysis of cisplatin and its metabolites in cancer patients: possible misinterpretation of covariates for pharmacokinetic parameters calculated from the concentrations of unchanged cisplatin, ultrafiltered platinum and total platinum.
Hanada K; Nishijima K; Ogata H; Atagi S; Kawahara M
Jpn J Clin Oncol; 2001 May; 31(5):179-84. PubMed ID: 11450990
[TBL] [Abstract][Full Text] [Related]
34. Creatinine clearance as a predictor of ultrafilterable platinum disposition in cancer patients treated with cisplatin: relationship between peak ultrafilterable platinum plasma levels and nephrotoxicity.
Reece PA; Stafford I; Russell J; Khan M; Gill PG
J Clin Oncol; 1987 Feb; 5(2):304-9. PubMed ID: 3806171
[TBL] [Abstract][Full Text] [Related]
35. Cisplatin pharmacokinetics using a five-day schedule during repeated courses of chemotherapy in germ cell tumors.
Bonetti A; Franceschi T; Apostoli P; Messori A; Sperotto L; Cetto GL; Molino A; Leone R
Ther Drug Monit; 1995 Feb; 17(1):25-32. PubMed ID: 7725373
[TBL] [Abstract][Full Text] [Related]
36. Comparison of renal function parameters in the assessment of cis-platin induced nephrotoxicity.
Verplanke AJ; Herber RF; de Wit R; Veenhof CH
Nephron; 1994; 66(3):267-72. PubMed ID: 7910667
[TBL] [Abstract][Full Text] [Related]
37. Phase I trial and pharmacokinetic study of pyrazoloacridine in children and young adults with refractory cancers.
Berg SL; Blaney SM; Adamson PC; O'Brien M; Poplack DG; Arndt C; Blatt J; Balis FM
J Clin Oncol; 1998 Jan; 16(1):181-6. PubMed ID: 9440741
[TBL] [Abstract][Full Text] [Related]
38. [The pharmacokinetics of cisplatin and its influence on renal functions based on different infusion methods].
Takahashi A; Takagi M; Hishida H; Saji E; Takagi N; Amano H; Ogura Y
Gan To Kagaku Ryoho; 1987 Oct; 14(10):2944-50. PubMed ID: 3116947
[TBL] [Abstract][Full Text] [Related]
39. Cisplatin nephrotoxicity. Correlation with plasma platinum concentrations.
Kelsen DP; Alcock N; Young CW
Am J Clin Oncol; 1985 Feb; 8(1):77-80. PubMed ID: 4039530
[TBL] [Abstract][Full Text] [Related]
40. Organic anion transporter 5 (Oat5) renal expression and urinary excretion in rats treated with cisplatin: a potential biomarker of cisplatin-induced nephrotoxicity.
Bulacio RP; Torres AM
Arch Toxicol; 2013 Nov; 87(11):1953-1962. PubMed ID: 23649842
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
